Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-574-4770
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.01. View Bellerophon Therapeutics' Earnings History.
When is Bellerophon Therapeutics' next earnings date?
What price target have analysts set for BLPH?
2 Wall Street analysts have issued 12-month price objectives for Bellerophon Therapeutics' stock. Their forecasts range from $2.00 to $3.00. On average, they expect Bellerophon Therapeutics' stock price to reach $2.50 in the next year. This suggests a possible upside of 277.1% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics.
What is the consensus analysts' recommendation for Bellerophon Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics.
What are Wall Street analysts saying about Bellerophon Therapeutics stock?
Here are some recent quotes from research analysts about Bellerophon Therapeutics stock:
- 1. Maxim Group analysts commented, "Bellerophon reported 2Q19 with a net loss of ($4.1M) and $16.8M in cash on the balance sheet. At the current burn rate of ~$4M-$5M per quarter, the company should be funded through 1H20 and importantly through the next infection point; Cohort-2 data in PH-ILD expected by YE19." (8/9/2019)
- 2. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (5/15/2019)
- 3. HC Wainwright analysts commented, "Valuation and Risks. Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing." (1/29/2019)
Has Bellerophon Therapeutics been receiving favorable news coverage?
Media coverage about BLPH stock has been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Bellerophon Therapeutics.
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Spero Therapeutics (SPRO), LifeVantage (LFVN), AcelRx Pharmaceuticals (ACRX), TAIWAN LIPOSOME/S (TLC), Adamas Pharmaceuticals (ADMS), Nature's Sunshine Products (NATR), Cue Biopharma (CUE), Affimed (AFMD), Poxel (PXXLF), Newron Pharmaceuticals (NWPHF), American Brivision (Holding) (ABVC), Sol Gel Technologies (SLGL), Chimerix (CMRX), CytoDyn (CYDY) and Cerecor (CERC).
What other stocks do shareholders of Bellerophon Therapeutics own?
Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the folowing people:
- Fabian Tenenbaum, Chief Executive Officer & Director
- Assaf Korner, Chief Financial Officer & Secretary
- Amy Edmonds, VP-Clinical Operations & Administration
- Martin Dekker, Vice President-Engineering & Manufacturing
- Peter Fernandes, Chief Regulatory & Safety Officer
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Who are Bellerophon Therapeutics' major shareholders?
Bellerophon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.08%), Vanguard Group Inc. (1.67%) and LPL Financial LLC (0.19%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View Institutional Ownership Trends for Bellerophon Therapeutics.
Which major investors are buying Bellerophon Therapeutics stock?
BLPH stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC and LPL Financial LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View Insider Buying and Selling for Bellerophon Therapeutics.
How do I buy shares of Bellerophon Therapeutics?
Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellerophon Therapeutics' stock price today?
One share of BLPH stock can currently be purchased for approximately $0.6630.
How big of a company is Bellerophon Therapeutics?
Bellerophon Therapeutics has a market capitalization of $45.69 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($0.34) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.View Additional Information About Bellerophon Therapeutics.
What is Bellerophon Therapeutics' official website?
How can I contact Bellerophon Therapeutics?
Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]
MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
